Navigation Links
Sunesis Presents Data Supporting SNS-032's Potential Anticancer,Activity in Multiple Myeloma at the American Association for Cancer,Research Meeting

were presented today as part of the Targeted Agents and Other Novel Therapies session in poster "SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives apoptosis in the multiple myeloma cell line RPMI-8226" (Abstract #1815).

About SNS-032

SNS-032 is a potent and selective inhibitor of CDKs 2, 7 and 9, which are critical in the communication and relay of signals to promote cellular growth and function. CDK2 is involved in cellular proliferation by regulating the initiation of and progression through the DNA-synthesis phase of the cell cycle. CDK7 and CDK9 are involved in transcriptional regulation of certain proteins involved in cell survival. Inappropriate activity by these CDKs can lead to unregulated proliferation, avoidance of apoptosis and increased cell survival, all of which are hallmarks of cancer. By selectively targeting these CDKs, SNS-032 may halt both aberrant cell proliferation and induce apoptosis.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell cycle and survival signaling. Sunesis is currently conducting Phase 2 clinical trials in lung and ovarian cancer and a Phase 1 clinical trial in acute myeloid leukemia for its lead compound, SNS-595. SNS-032, Sunesis' CDK inhibitor compound, is being evaluated in Phase 1 clinical trials in B-cell malignancies and in advanced solid tumors. The company's Aurora kinase inhibitor, SNS-314 is expected to begin Phase 1 clinical trials in the first half of 2007. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other oncology kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has buil
'"/>




Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
8. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
9. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
10. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
11. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
Post Your Comments:
(Date:10/22/2014)... 2014  CryoLife, Inc. (NYSE: CRY ), ... on cardiac and vascular surgery, announced today that ... Officer, has been elected to the Company,s Board of ... G. Anderson , Executive Chairman of CryoLife, stated, "Since joining ... an excellent leader who is well positioned to maximize ...
(Date:10/22/2014)... , Oct. 21, 2014  Early symptoms of ... or unnoticed, but new technology, coupled with yearly, ... leading to earlier detection of eye diseases, including ... million Americans. If left untreated, these diseases can ... Recently, optometric researchers have deployed ...
(Date:10/22/2014)... , Oct. 22, 2014 InVivo Therapeutics ... MA is revolutionizing spinal cord injury (SCI) ... been shown to outperform in tissue regrowth in the ... scaffold.  Made from an FDA approved polymer, the scaffold ... it harmless to the human body. NVIV has recently ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... COPD Day, Physicians Urged to Use Wider Screening Criteria for ... Alpha-1 Antitrypsin Deficiency, ... finds that a,higher than expected number of COPD and severe asthma ... for broader,criteria for AAT deficiency testing. AAT deficiency, also known as ...
... -- Data Presented at Anti-Angiogenesis Conference Shows R84, the Selective ... Affitech, Is Equivalent to Avastin in Inhibiting Growth ... Tumors in a Preclinical Breast Cancer ... Advanced as a Potential Clinical Candidate --, BOSTON and ...
Cached Medicine Technology:Study Shows Need to Test More COPD and Asthma Patients for Underdiagnosed Pulmonary Disease 2Study Shows Need to Test More COPD and Asthma Patients for Underdiagnosed Pulmonary Disease 3Study Shows Need to Test More COPD and Asthma Patients for Underdiagnosed Pulmonary Disease 4Study Shows Need to Test More COPD and Asthma Patients for Underdiagnosed Pulmonary Disease 5New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 2New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 3New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 4New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 5
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- The United ... arriving from Ebola-affected nations of West Africa land ... them for infection with the virus. In ... Johnson noted that 94 percent of air passengers ... at one of these five airports -- New ...
(Date:10/22/2014)... Grants Pass, OR (PRWEB) October 22, 2014 ... while Southern California’s fresh water supply runs dangerously low, ... climate change. Southern Oregon’s rivers, despite the lowest mountain ... fast even in late summer and early autumn.* That ... Urness, authors of the new book “Hiking Southern Oregon,” ...
(Date:10/22/2014)... Lintelus, Inc., an event software provider, ... Sales, will be speaking on the subject of “Event ... October 28, at the Holiday Inn in New York ... well as a Tech Demo at 12:45pm, to educate ... more engaging event experience. , The Annual Meetings Technology ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- Two sisters ... and heart damage. Ilina and Medha Krishen use ... for sounds of trouble in breathing patterns or heartbeats. ... School in Michigan, wanted to find a way to ... air pollutants. Using an electronic stethoscope, Ilina recorded one ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... Ebola while working for NBC News in Liberia has ... isolation unit at Nebraska Medical Center in Omaha, where he had ... A blood test confirmed by the U.S. Centers for Disease ... to Providence, R.I., NBC News reported Tuesday night. ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
... , WEDNESDAY, Oct. 5 (HealthDay News) -- ,Raw ... could affect human health, a new study suggests. ... have been identified worldwide. In this study, researchers ... raw sewage in North America, Europe and Africa. They ...
... (HealthDay News) -- Three hours of vigorous exercise a week ... a new study suggests. The Harvard School of Public ... decreased risk was due to the beneficial effects of exercise ... The findings were published Oct. 4 the journal ...
... 4 (HealthDay News) -- ,Obesity and alcohol consumption are among ... coronary artery disease, a new study finds. Researchers analyzed ... died of sudden cardiac death -- in which the heart ... and 2007, along with the patients, hospital records and questionnaires ...
... , TUESDAY, Oct. 4 (HealthDay News) -- ,A ... people are better able to remember details of past events ... about or may have imagined, scientists report. The study ... took memory tests. Participants who lacked a fold at the ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... in drunk driving since 2006, drunk drivers still account for ... -- each year in the United States, according to the ... incidents peaked in 2006, and decreased nearly one-third through 2010, ...
... gathering of international experts will be charting the unfolding ... consumer. Thought leaders from academic medical centers, government, and ... genomic information to develop new treatments and cures. Held ... of Pennsylvania on October 18 and 19, the 6th ...
Cached Medicine News:Health News:Raw Sewage a New Frontier for Scientists 2Health News:Alcohol, Obesity Major Causes of Sudden Heart Death 2Health News:MRI Study Unfolds Clues to Memory 2Health News:Drunk Driving Declines in U.S. 2Health News:Drunk Driving Declines in U.S. 3Health News:6th Annual International Translational Medicine Symposium held at Penn 2Health News:6th Annual International Translational Medicine Symposium held at Penn 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: